Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer (ELENI)
Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer: a Multicenter, National, Prospective Non-interventional Study
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Laura Serrer
- Numero di telefono: +49761152420
- Email: eleni@iomedico.com
Luoghi di studio
-
-
-
Freiburg im Breisgau, Germania, 79110
- Reclutamento
- Praxis für interdisziplinäre Onkologie & Hämatologie
-
Contatto:
- Patrick Marschner
- Numero di telefono: +49761386870
- Email: klifo@onkologie-freiburg.de
-
Paderborn, Germania, 33098
- Reclutamento
- St. Louise Frauen- und Kinderklinik
-
Contatto:
- Michael P Lux
- Numero di telefono: +49 5251864121
- Email: M.Lux@vincenz.de
-
Ravensburg, Germania, 88212
- Reclutamento
- Gemeinschaftspraxis für Hämatologie und Onkologie
-
Contatto:
- Thomas Decker
- Numero di telefono: +49 751 366197-0
- Email: thomas.decker@onkonet.eu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Signed and dated informed consent form
- Postmenopausal women
- Age ≥18 years
- Eastern Cooperative Oncology Group Performance Status (ECOG) < 2
- Locally advanced and/or metastatic ER+ HER2- breast cancer
- Histologically proven ER positivity (defined as ≥1% staining by immunohistochemistry (IHC))
- Histologically proven HER2 negativity (defined as a IHC0 or IHC1+ score by IHC or a negative result by in situ hybridization (ISH), optionally combined with a IHC2+ score)
- Disease progression following first line ET + CDKi
- No more than one prior ET line in the advanced/metastatic setting and intention for 2nd-line treatment with elacestrant according to current elacestrant SmPC as assessed by the treating physician (ESR1 testing can be done after inclusion)
- For patients with proven ESR1mut: Study inclusion the latest 2 weeks after start of elacestrant treatment
Exclusion Criteria
- Prior chemotherapy in the advanced/metastatic setting
- Contraindications according to elacestrant SmPC, except for ESR1 test result for patients included prior to ESR1 testing.
- Participation in an interventional clinical trial within 30 days prior to enrolment or simultaneous participation in an interventional clinical trial (except follow-up phase)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Numero di gruppi/coorti
Coorti e interventi
Gruppo / CoorteGruppo / Coorte |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
ESR1 wildtype
Patients with a ESR1 wildtype tumor
|
Treatment decision of investigator
|
|
ESR1 mutated
Patients with a ESR1 mutated tumor
|
According to the Summary of Product Characteristics (SmPC)
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change from baseline in EORTC global health scale
Lasso di tempo: From Time of enrollment until month 11
|
Change from baseline quality of life (QoL) over time for the global health scale of the EORTC QLQ- C30 questionnaire The EORTC QLQ- C30 global health scale ranges from 0 to 100, with higher scores indicating better quality of life.
|
From Time of enrollment until month 11
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Valutare i parametri del processo decisionale terapeutico da parte dei medici utilizzando un questionario
Lasso di tempo: Linea di base
|
Frequenza di parametri distinti che influenzano la scelta della terapia; questionario compilato dal medico curante.
|
Linea di base
|
|
Time to deterioration in global health scale (EORTC QLQ-C30)
Lasso di tempo: From Time of enrollment until month 11
|
Time to deterioration in global health scale of EORTC QLQ-C30 The EORTC QLQ- C30 global health scale ranges from 0 to 100, with higher scores indicating better quality of life.
|
From Time of enrollment until month 11
|
|
Time to deterioration in functional scores (EORTC QLQ-C30)
Lasso di tempo: From Time of enrollment until month 11
|
Time to deterioration in functional scores of EORTC QLQ-C30.
The EORTC QLQ- C30 functional score ranges from 0 to 100, with higher scores indicating better quality of life.
|
From Time of enrollment until month 11
|
|
Time to deterioration in symptom scores (EORTC QLQ-C30)
Lasso di tempo: From Time of enrollment until month 11
|
Time to deterioration in symptom scores of EORTC QLQ-C30 The EORTC QLQ- C30 symptom score ranges from 0 to 100, with lower scores indicating better quality of life.
|
From Time of enrollment until month 11
|
|
Change from baseline in functional and symptom scores
Lasso di tempo: From Time of enrolment until up to 11 months after enrolment.
|
Change from baseline in functional and symptom scores of EORTC QLQ-C30 The EORTC QLQ- C30 functional and symptom scores ranges from 0 to 100, with higher scores indicating better quality of life (for functional scores), and lower indication better quality of life for symptom scores.
|
From Time of enrolment until up to 11 months after enrolment.
|
|
Change from baseline in visual analogue scale (VAS)
Lasso di tempo: From Time of enrollment until month 11.
|
Change from baseline in EQ-5D-5L visual analogue scale (VAS); The EQ-5D-5L VAS ranges from 0 to 100, with higher scores indicating better quality of life.
|
From Time of enrollment until month 11.
|
|
Change from baseline in index value
Lasso di tempo: From Time of enrollment until month 11.
|
Change from baseline in EQ-5D-5L Index Value The EQ-5D-5L index value ranges from -0.661 to 1, with higher scores indicating better quality of life.
|
From Time of enrollment until month 11.
|
|
Change from baseline in all scales of EQ-5D-5L
Lasso di tempo: From Time of enrollment until month 11.
|
Change from baseline in all scales of EQ-5D-5L The scales of EQ-5D-5L range from 1 to 5, with lower scores indicating better quality of life.
|
From Time of enrollment until month 11.
|
|
Prevalence of ESR1 mutation
Lasso di tempo: Baseline
|
Assess prevalence of ESR1mut in patients intended for elacestrant treatment as well as the testing methodology and results for ESR1 mutations.
|
Baseline
|
|
Drug safety: Frequency
Lasso di tempo: From time of treatment start until 30 days after end of elacestrant treatment
|
Frequency of specific (serious) adverse drug reactions ((S)ADRs) (nausea, vomiting, decreased appetite)
|
From time of treatment start until 30 days after end of elacestrant treatment
|
|
Drug safety: Incidence of adverse events
Lasso di tempo: From time of treatment start until 30 days after end of elacestrant treatment
|
Incidence of (serious) adverse events ((S)AEs), (serious) adverse drug reactions ((S)ADRs)
|
From time of treatment start until 30 days after end of elacestrant treatment
|
|
Drug safety: Change from baseline in AST (Aspartate Aminotransferase)
Lasso di tempo: From time of treatment start until 30 days after end of elacestrant treatment (max. 24 months)
|
Change from baseline in AST
|
From time of treatment start until 30 days after end of elacestrant treatment (max. 24 months)
|
|
Drug safety: Change from baseline in ALT (Alanine Aminotransferase)
Lasso di tempo: From time of treatment start until 30 days after end of elacestrant treatment (max. 24 months)
|
Change from baseline in ALT
|
From time of treatment start until 30 days after end of elacestrant treatment (max. 24 months)
|
|
Drug safety: Change from baseline in bilirubin
Lasso di tempo: From time of treatment start until 30 days after end of elacestrant treatment (max. 24 months)
|
Change from baseline in bilirubin
|
From time of treatment start until 30 days after end of elacestrant treatment (max. 24 months)
|
|
Patients and disease characteristics: Age
Lasso di tempo: Baseline
|
Assess patients characteristics in patients with intention for treatment with elacestrant: Age (descriptive statistics, categorical (</≥ 65))
|
Baseline
|
|
Patients and disease characteristics: Body mass index (BMI)
Lasso di tempo: Baseline
|
Assess patients characteristics in patients with intention for treatment with elacestrant: BMI (descriptive statistics, categorical (underweight, normal weight, overweight, obese))
|
Baseline
|
|
Patients and disease characteristics: ECOG Performance status
Lasso di tempo: Baseline
|
Assess patients characteristics in patients with intention for treatment with elacestrant: ECOG Performance status
|
Baseline
|
|
Patients and disease characteristics: CCI (Charlson score and contributing diseases)
Lasso di tempo: Baseline
|
Assess patients characteristics in patients with intention for treatment with elacestrant: CCI (Charlson score and contributing diseases)
|
Baseline
|
|
Patients and disease characteristics: Time since diagnosis
Lasso di tempo: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: Time since diagnosis (descriptive statistics)
|
Baseline
|
|
Patients and disease characteristics: TNM staging
Lasso di tempo: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: TNM staging (including AJCC) at initial diagnosis
|
Baseline
|
|
Patients and disease characteristics: Metastatic sites
Lasso di tempo: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: • Metastatic sites at inclusion
|
Baseline
|
|
Patients and disease characteristics: Tumor Grading
Lasso di tempo: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: Tumor Grading at initial diagnosis and inclusion
|
Baseline
|
|
Patients and disease characteristics: HR and HER2 status
Lasso di tempo: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: HR status and HER2 status at initial diagnosis and at inclusion
|
Baseline
|
|
Patients and disease characteristics: Prior adjuvant chemotherapy
Lasso di tempo: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: Prior adjuvant chemotherapy
|
Baseline
|
|
Patients and disease characteristics: Prior adjuvant endocrine therapy
Lasso di tempo: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: Prior adjuvant endocrine therapy
|
Baseline
|
|
Patients and disease characteristics: prior CDKi/endocrine therapy in the palliative setting
Lasso di tempo: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: Type and duration of prior CDKi/endocrine therapy in the palliative setting (descriptive statistics, categorical ≤6 months / >6 months; ≤12 months / >12 months)
|
Baseline
|
|
Patients and disease characteristics: Disease site
Lasso di tempo: At time of enrollment
|
Assess disease characteristics in patients with intention for treatment with elacestrant: Disease site (bone-only / visceral / non-visceral (not bone-only)) at inclusion
|
At time of enrollment
|
|
Patients and disease characteristics: concomitant diseases
Lasso di tempo: Baseline
|
Assess disease characteristics in patients with intention for treatment with elacestrant: concomitant diseases
|
Baseline
|
|
Use of concomitant medication
Lasso di tempo: max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
Assess the use of concomitant medication during treatment with elacestrant.
|
max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
|
Frequency of first subsequent systemic antineoplastic therapy for ESR1wt patients and ESR1mut patients without elacestrant treatment
Lasso di tempo: max. 24 months; at patient patient-specific start of treatment
|
Assess second-line treatments for all patients by ESR1 status (Frequency of first subsequent systemic antineoplastic therapy for ESR1wt patients and ESR1mut patients without elacestrant treatment (refers to first treatment received starting from second line)
|
max. 24 months; at patient patient-specific start of treatment
|
|
Details on treatment with elacestrant: reason for end of treatment
Lasso di tempo: max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
Assess reason for end of treatment (treatment with elacestrant)
|
max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
|
Details on treatment with elacestrant: dose intensity
Lasso di tempo: max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
Assess dose intensity (treatment with elacestrant) as prescribed by the treating physician
|
max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
|
Details on treatment with elacestrant: frequency and type of dose modification
Lasso di tempo: max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
Assess Frequency and type of dose modifications (dose reductions, interruptions) compared to SmPC of elacestrant.
|
max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
|
Details on treatment with elacestrant: reasons for dose modifications and interruptions
Lasso di tempo: max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
Assess reasons for dose modifications and interruptions (elacestrant treatment)
|
max. 24 months; from the patient-specific study start to end of study (during elacestrant treatment)
|
|
Treatments following elacestrant therapy: Type of first subsequent systemic antineoplastic therapy
Lasso di tempo: max. 24 months; from the patient-specific end of elacestrant treatment until end of study
|
Details on treatments following elacestrant therapy (Type of first subsequent systemic antineoplastic therapy)
|
max. 24 months; from the patient-specific end of elacestrant treatment until end of study
|
|
Treatments following elacestrant therapy: Frequency of first subsequent systemic antineoplastic therapy
Lasso di tempo: max. 24 months; from the patient-specific end of elacestrant treatment until end of study
|
Details on treatments following elacestrant therapy:Frequency of first subsequent systemic antineoplastic therapy for ESR1mut patients (refers to first treatment received after Elacestrant so starting from third line)
|
max. 24 months; from the patient-specific end of elacestrant treatment until end of study
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Thomas Decker, Professor, Gemeinschaftspraxis für Hämatologie und Onkologie GbR Ravensburg
- Investigatore principale: Michael Patrick Lux, Professor, St. Louise Frauen- und Kinderklinik Paderborn
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie della pelle
- Malattie del seno
- Malattie della pelle e del tessuto connettivo
- Neoplasie mammarie
- Amministrazione dei servizi sanitari
- Qualità, accesso e valutazione dell'assistenza sanitaria
- Qualità dell'assistenza sanitaria
- Indicatori di qualità, assistenza sanitaria
- Standard di cura
- Elacestrant
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- IOM-090506
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .